.png)
What Happens If You Stop Your GLP-1? The Research on Weight Regain, Explained
- Manaloahealth
- Jul 3
- 4 min read
If you're on a GLP-1 medication like semaglutide or tirzepatide, there's a question that tends to creep in eventually, often quietly, sometimes anxiously: what happens if I have to stop?
Cost increases. Insurance coverage changes. Side effects. Life circumstances. There are a lot of legitimate reasons people consider stopping a GLP-1, and the honest answer about what happens next deserves more than a vague reassurance. Here's what the most current research actually shows, and more importantly, what to do about it.
The Data on Stopping
A large meta-analysis published in The BMJ in January 2026 looked at this question directly.[1] Drawing on data from over 9,000 participants across 37 studies of weight-loss medications, the researchers found that after stopping treatment, people return to their baseline weight in an average of just 1.7 years.[2] The average rate of regain was about 0.4 kg per month, roughly four times faster than the rate of regain seen after stopping behavioral interventions like diet and exercise programs alone, regardless of how much weight was lost in the first place.[2]
It's not just the weight that comes back. The same analysis found that stopping these medications is followed not only by weight regain but by a reversal of the beneficial effects on heart and metabolic health markers, including cholesterol and blood pressure, with those markers predicted to return to pre-treatment levels in less than two years. BMJ GroupBMJ Group
This isn't a fringe finding. A separate, more recent systematic review of 18 randomized controlled trials found a similar pattern: stopping treatment led to significant metabolic rebound, including measurable increases in body weight, blood sugar markers, waist circumference, and blood pressure.[3] That same review found the rebound tends to be worse the longer someone stays off the medication, and somewhat more pronounced with semaglutide than with older GLP-1 drugs.[3]
Why This Happens
It's worth being clear about what this data does and doesn't mean. It doesn't mean the medication "failed," or that the weight loss wasn't real. As one accompanying editorial in The BMJ put it plainly: "GLP-1 receptor agonists should not be relied on as a magic cure for treating obesity... people using [GLP-1s] should be aware of the high discontinuation rate and the consequences of cessation of medications. Healthy dietary and lifestyle practises should remain the foundation for obesity treatment and management, with medications such as [GLP-1s] used as adjuncts." Medscape
In plain terms: obesity is increasingly understood as a chronic condition, the same way high blood pressure or type 2 diabetes is. GLP-1 medications work by changing underlying appetite and metabolic signaling. When the medication stops, those signals tend to drift back toward where they started, especially without something else in place to support the change.
This also explains a related, less-discussed finding. Research presented at ENDO 2026 analyzing health data from millions of GLP-1 users found that the majority of people who discontinue these medications eventually restart treatment, primarily driven by weight regain and worsening metabolic markers. Stopping often isn't the end of the story. For many people, it's the beginning of a cycle of stopping and restarting, often without much of a plan in between. Medical Daily
What Actually Helps
This is the part that doesn't get talked about enough: discontinuation outcomes are not all-or-nothing. The research on tapering and maintenance dosing, while still developing, points to a few consistent themes that are worth discussing with your provider before making any change:
Stopping isn't necessarily all-or-nothing. For many patients, an ongoing lower maintenance dose, rather than full discontinuation, helps sustain results with fewer side effects and sometimes lower cost.
A planned, gradual taper tends to outperform stopping abruptly, giving your body, and your provider, time to monitor appetite return and intervene early if regain starts.
Whatever happens with the medication, the habits built during treatment (protein intake, resistance training, consistent routines) are the strongest predictor of what happens to your weight afterward.
None of this is a one-size-fits-all protocol. It's a conversation that needs to happen with a provider who already knows your history, your labs, and your goals, ideally well before you're forced into a decision by a refill running out.
The Mana Loa Approach
This is exactly the gap that a one-time prescription or a mail-order GLP-1 subscription doesn't fill. Stopping a GLP-1 without a plan isn't a small decision, and the data shows it has real, measurable consequences if it's handled reactively instead of proactively.
At Mana Loa Health, your treatment plan doesn't end at the prescription. Whether you're just getting started, adjusting your dose, or thinking through what long-term maintenance looks like for you, you have direct, ongoing access to a provider who can help you plan for what's next, instead of finding out the hard way. If cost, access, or side effects are making you consider stopping, talk with us first. There's almost always a better path than going cold.
Currently treating patients located in:
Colorado, Florida, Hawaii, and Washington!
Click the link to schedule a consultation today!
-The Mana Loa Health Team
Patient safety is Mana Loa Health's top priority. The information discussed on this blog is not intended to recommend the self management of health problems or wellness. It is not intended to endorse or recommend any particular type of medical treatment or advice. The information provided on this website is for informational purposes and not a substitute for professional medical advice, diagnosis, or treatment. If you have questions or concerns about your health, please talk to your healthcare provider. No information contained on this blog should be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider.
References
West S, et al. Trajectory of weight and cardiometabolic risk factors after discontinuation of anti-obesity medications: systematic review and meta-analysis. The BMJ, January 7, 2026.
Weight Regain, Health Benefit Loss Rapid When GLP-1s Stopped. Medscape, reporting on the BMJ study, January 2026.
Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis. PMC (PubMed Central).
ENDO 2026 Study Finds Most People Who Stop Ozempic or Tirzepatide for Type 2 Diabetes Eventually Restart Treatment. Medical Daily, reporting on ENDO 2026.
Comments